Abstract:Abstract Bruton’s tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies. BTK was initially shown to be defective in the primary immunodeficiency X-linked agammaglobulinemia (XLA) and is essential both for B cell development and function of mature B cells. Shortly after its discovery, BTK was placed in the signal transduction pathway downstream of the B cell antigen receptor (BCR). More recently, small-molecule inhibitors of this kinase have shown excellent anti-tumor activity, first in animal models and subsequently in clinical studies. In particular, the orally administered irreversible BTK inhibitor ibrutinib is associated with high response rates in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and mantle-cell lymphoma (MCL), including patients with high-risk genetic lesions. Because ibrutinib is generally well tolerated and shows durable single-agent efficacy, it was rapidly approved for first-line treatment of patients with CLL in 2016. To date, evidence is accumulating for efficacy of ibrutinib in various other B cell malignancies. BTK inhibition has molecular effects beyond its classic role in BCR signaling. These involve B cell-intrinsic signaling pathways central to cellular survival, proliferation or retention in supportive lymphoid niches. Moreover, BTK functions in several myeloid cell populations representing important components of the tumor microenvironment. As a result, there is currently a considerable interest in BTK inhibition as an anti-cancer therapy, not only in B cell malignancies but also in solid tumors. Efficacy of BTK inhibition as a single agent therapy is strong, but resistance may develop, fueling the development of combination therapies that improve clinical responses. In this review, we discuss the role of BTK in B cell differentiation and B cell malignancies and highlight the importance of BTK inhibition in cancer therapy.

Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features

BTK Inhibitors in CLL: Second Generation Drugs and Beyond

Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial

BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies

Covalent Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia

Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma

BTK inhibitors: past, present, and future

Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials

Targeting Bruton's tyrosine kinase in B cell malignancies

Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib

Role of Bruton’s tyrosine kinase in B cells and malignancies

BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia

Targeting Bruton’s Tyrosine Kinase in CLL

Targeting Bruton's Tyrosine Kinase in CLL

Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia.

BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects

Evaluation of second-generation Bruton's tyrosine kinase inhibitors for the treatment of mantle cell lymphoma

Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances

New means and challenges in the targeting of BTK

Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies

The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies